MedImmune signs on for immunotherapy combo testing with cancer institutes
This article was originally published in Scrip
Executive Summary
As the first company to sign up for a cancer immunotherapy collaboration with the Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research, AstraZeneca's biologics business arm MedImmune sees value in letting independent investigators evaluate immunotherapeutic combinations in early-stage clinical trials.